1 Attard, G., et al. (2025, May). Phase 3 AMPLITUDE trial: Niraparib and abiraterone acetate plus prednisone for metastatic castration-sensitive prostate cancer patients with alterations in homologous ...

(UroToday.com) The 2025 ASCO annual meeting featured a urothelial carcinoma rapid oral abstract session and a presentation by Dr. Xinan Sheng discussing results from a phase 1b/2 study assessing ...

(UroToday.com) The 2025 SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Benjamin Garmezy discussing a phase 1 trial of mevrometostat (PF-06821497), a potent and ...

(UroToday.com) The 2025 PSMA and Beyond annual meeting featured a PSMA session and a presentation by Dr. Amir Iravani discussing the landscape of approved PSMA imaging agents. Over the last several ...

(UroToday.com) The 2025 ASCO annual meeting featured a kidney cancer rapid oral abstract session and a presentation by Dr. James Geller discussing results of AREN1721, a randomized phase 2 trial of ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Kidney and ...

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Pornlada Likasitwatanakul discussing the effect of HLA class I expression on the tumor immune ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers poster session.

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Session State of the Art Lecture: Personalizing treatment for patients with ...

ASCO 2025 post-hoc analysis of TheraP, clonal hematopoiesis, metastatic castration-resistant prostate cancer (mCRPC), 177Lu-PSMA-617, cabazitaxel, PSMA-targeted radioligand.

ASCO GU 2025 STARLITE 2 trial in progress, nivolumab plus 177lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients with advanced clear ...

ASCO 2025, bladder cancer, muscle-invasive bladder cancer (MIBC), trimodal therapy (TMT), SWOG 8710 trial, PURE-01 trial, NIAGARA trial, ABACUS trial, CheckMate 274 trial, ImVigor 010, atezolizumab, ...